Physician profile
Mark A Braniecki
NPI 1558463695
$1,376.41
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $156 · 2021: $395 · 2022: $325 · 2023: $209 · 2024: $93.42.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $301.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $294.18 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $188.79 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $113.78 | 2019-2021 | |
| Glaxosmithkline, LLC. | $98.28 | 2019-2022 | |
| Novo Nordisk INC | $97.27 | 2022-2024 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $87.43 | 2023-2024 | |
| Sanofi Pasteur INC. | $73.12 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $63.33 | 2019-2021 | |
| Cardiovascular Systems INC. | $60.52 | 2021 | |
| Amgen INC. | $51.31 | 2020-2022 | |
| Exact Sciences Corporation | $46.27 | 2023 | Cologuard Collection Kit |
| Eisai INC. | $42.03 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $38.36 | 2023 | Fasenra |
| Takeda Pharmaceuticals U.S.A., INC. | $32.82 | 2022-2023 | Gattex |
| Alexion Pharmaceuticals, INC. | $16.91 | 2023 | Strensiq |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $15.70 | 2021 | |
| Novartis Pharmaceuticals Corporation | $15.29 | 2021 | |
| Mylan Specialty L.P. | $14.93 | 2020 | |
| Idorsia Pharmaceuticals US INC | $13.98 | 2023 | Quviviq |
| Amarin Pharma, INC. | $12.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Braniecki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.